A multi‑site UC Health analysis of more than 6,800 colon cancer patients found those prescribed GLP‑1 receptor agonists had substantially lower five‑year mortality versus non‑users, with adjusted estimates indicating roughly half the death rate. The observational study used real‑world electronic health records and controlled for comorbidities and treatments. The finding arrives as GLP‑1 sales surge: third‑quarter global sales topped $20 billion, driven by diabetes and obesity indications. Researchers and clinicians cautioned that observational data do not prove causation and urged prospective trials to assess mechanisms and potential confounding.